KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Pipeline Review, H1 2016

  • ID: 3734781
  • Report
  • 34 pages
  • Global Markets Direct
1 of 4
KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Pipeline Review, H1 2016

Summary

‘KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Pipeline Review, H1 2016’, provides in depth analysis on KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) targeted pipeline therapeutics.

The report provides comprehensive information on the KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54)
- The report reviews KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) targeted therapeutics and enlists all their major and minor projects
- The report assesses KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Introduction

Report Coverage

KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) Overview

Therapeutics Development

KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Products under Development by Stage of Development

KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Products under Development by Therapy Area

KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Products under Development by Indication

KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Pipeline Products Glance

Late Stage Products

Early Stage Products

KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Products under Development by Companies

KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Products under Development by Universities/Institutes

KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Companies Involved in Therapeutics Development

Crinetics Pharmaceuticals, Inc.

Millennium Pharmaceuticals, Inc.

KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Drug Profiles

Kisspeptin-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

kisspeptin-54 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-448 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Discontinued Products

KiSS-1 Receptor (G-Protein Coupled Receptor 54 or G-Protein Coupled Receptor OT7T175 or hOT7T175 or Hypogonadotropin-1 or Kisspeptins Receptor or Metastin Receptor or KISS1R or GPR54) - Featured News & Press Releases

Jan 28, 2015: Crinetics Pharmaceuticals Awarded $1.5MM NIH Phase-II SBIR Grant to Develop Kisspeptin Receptor Antagonists for PCOS and Other Women’s Health Diseases

Jun 18, 2013: Kisspeptin hormone could make IVF safer for mothers

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Crinetics Pharmaceuticals, Inc., H1 2016

Pipeline by Millennium Pharmaceuticals, Inc., H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll